Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Conditions
Interventions
None listed
Sponsors
National Biopharma Mission NBM Biotechnology Industry Research Assistance Council BIRAC
Eligibility
Inclusion criteria
Inclusion criteria: Survey will be carried out in individuals above 2 years of age and individuals currently residing and likely to stay till the end of the study (1 year) in the study area will be considered eligible for inclusion
Exclusion criteria
Exclusion criteria: Consent Refusal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Incidence rate of acute febrile illness episode during 12 months of follow up 2. b.Incidence rate of symptomatic laboratory confirmed Dengue infection episodes during 12 months of follow up 3. c.Incidence of Sero positivity based on IgG, IgM and neutralizing antibodies at 12 months (Sero Negative for IgG, IgM or Neutralizing antibodies at baseline at enrolment)Timepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Incidence rate of symptomatic laboratory-confirmed Chikungunya infection episodes during 12 months of follow up 2. Determine etiology of AFI due to other common causes of AFI (based on rapid diagnostic or ELISA tests) a. Malaria b. Scrub typhus c. Leptospirosis d. Typhoid 3. Describe proportion of symptomatic versus asymptomatic or subclinical infections of dengue and chikungunya based on data obtained from primary objectives. 4. Identify and describe circulating serotypes of dengue, chikungunya in general population 5. To assess spatiotemporal trend of Dengue and Chikungunya infection 6. Determine the durability of IgG, IgM and Neutralizing antibodies in symptomatic individuals tested n positive for Dengue and Chikungunya infection. 7. Estimate the economic burden of dengue and chikungunya fevers based on information about: a. Patients with severe illness requiring hospitalization and / or ICU care b. Patients managed on out-patient basis. Timepoint: 12 months | — |
Countries
India
Contacts
Public ContactDr R Prabhu
ICMR National Institute of Epidemiology Chennai
Outcome results
None listed